Protocol Ledger

NCT04777851 · Phase III · TERMINATED

Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7

Interventional Phase III clinical trial protocol NCT04777851 sponsored by Translational Research in Oncology in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-10-11 Enrollment: 45 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04777851
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)45 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04777851
Protocol FieldVerified Registry Value
NCT IdentifierNCT04777851
Consolidated Lead SponsorTranslational Research in Oncology
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment45 participants (ACTUAL)
Registered Start Date2023-10-11
WhyStopped ClassificationInsufficient / Slow Accrual

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04777851
Hospital Research SiteLocationSite Profile
UCLA Health and Jonsson Comprehensive Cancer CenterLos Angeles, CAOpen Hospital Dossier ->
Inje University Haeundae Paik HospitalBusan, South KoreaOpen Hospital Dossier ->
Severance Hospital, Yonsei University Health SystemSeoul, South KoreaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI